NCT03899909View on ClinicalTrials.gov

A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 29, 2019

Primary Completion Date

June 3, 2019

Study Completion Date

June 3, 2019

Conditions
Healthy
Interventions
DRUG

GLPG3121 SAD

GLPG3121 oral suspension, single ascending doses

DRUG

Placebo SAD

Placebo oral suspension

DRUG

GLPG3121 MAD

GLPG3121 oral suspension, multiple ascending doses, daily for 13 days

DRUG

Placebo MAD

Placebo oral suspension, daily for 13 days

Trial Locations (1)

2060

SGS Belgium NV - Clinical Pharmacology Unit Antwerp, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT03899909 - A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects | Biotech Hunter | Biotech Hunter